CASSI GRIMES: Open Payments
NPI 1962153718 · OSAWATOMIE, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$555 in 8 payments from 8 companies in 2025. Trend: 2023 $111 · 2024 $0 · 2025 $555
Food & beverage: $555
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 1 | $137 |
| GlaxoSmithKline, LLC. | 1 | $122 |
| Averitas Pharma Inc. | 1 | $113 |
| Edwards Lifesciences Corporation | 1 | $108 |
| Novo Nordisk Inc | 1 | $28 |
| Ardelyx, Inc. | 1 | $17 |
| ABBVIE INC. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
Products named: AREXVY, QUTENZA, SAPIEN 3 Ultra RESILIA, Wegovy, IBSRELA, VRAYLAR, REXULTI.
Industry payments across KS — which companies pay providers there.
